<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03419403</url>
  </required_header>
  <id_info>
    <org_study_id>M16-534</org_study_id>
    <secondary_id>2017-003171-64</secondary_id>
    <nct_id>NCT03419403</nct_id>
  </id_info>
  <brief_title>UNITE Study: Understanding New Interventions With GBM ThErapy</brief_title>
  <official_title>Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of several ophthalmologic prophylactic treatment
      strategies for the management of ocular side effects (OSEs) in participants with epidermal
      growth factor receptor (EGFR)-amplified glioblastoma (GBM) who are being treated with
      depatuxizumab mafodotin (ABT-414). The study will include 2 phases during the treatment
      period: chemoradiation therapy (radiation plus temozolomide [RT/TMZ]) and adjuvant therapy
      (TMZ ). All participants will receive depatuxizumab mafodotin during both phases of the
      treatment period plus 1 of 3 prophylactic ophthalmologic treatments (standard steroids [SS],
      standard steroids with vasoconstrictors and cold compress [SS/VC], and enhanced steroids with
      vasoconstrictors and cooling compress [ES/VC]).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 30, 2018</start_date>
  <completion_date type="Actual">March 3, 2020</completion_date>
  <primary_completion_date type="Actual">September 5, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants who Require a Change in Ocular Side Effect (OSE) Management</measure>
    <time_frame>Up to approximately 18 weeks after initial dose of depatuxizumab mafodotin</time_frame>
    <description>Ocular Side Effect (OSE) management is defined as a participant with &gt;= 3-line loss (+ 0.3 on LogMAR scale or equivalent) of best corrected visual acuity from baseline (with prescription at baseline for those using corrective lens), or &gt;= Grade 3 OSE severity on the Corneal Epithelial Adverse Event [CEAE] scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Dose of Depatuxizumab Mafodotin</measure>
    <time_frame>Up to approximately 18 weeks after initial dose of depatuxizumab mafodotin</time_frame>
    <description>Cumulative dose of depatuxizumab mafodotin administered (mg/kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline In Logarithm of the Minimum Angle of Resolution (LogMAR) Scale after Bandage Contact Lenses (BCL) Intervention</measure>
    <time_frame>Up to approximately 18 weeks after initial dose of depatuxizumab mafodotin</time_frame>
    <description>Change on LogMAR Scale from last assessment prior to BCL intervention to 2 weeks after BCL intervention. The LogMAR scale measures visual acuity on a continuous scale, with a LogMAR value of 0 equivalent to 20/20 visual acuity. Normal vision is considered to be from -0.2 - 0.1; higher values indicate visual impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to OSE Symptom Resolution after Drug Discontinuation (reversibility)</measure>
    <time_frame>Up to approximately 3 years after initial dose of depatuxizumab mafodotin</time_frame>
    <description>Time from discontinuation of depatuxizumab mafodotin to OSE symptom resolution (reversibility).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to BCL Intervention</measure>
    <time_frame>Up to approximately 18 weeks after initial dose of depatuxizumab mafodotin</time_frame>
    <description>Time to initiation of bandage contact lenses (BCL) intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants that recover to &lt;3-line decline from Baseline (&lt;= +0.3 LogMAR) in visual acuity after BCL Intervention</measure>
    <time_frame>Up to approximately 18 weeks after initial dose of depatuxizumab mafodotin</time_frame>
    <description>Recovery is defined as return to &lt;3-line decline from baseline (&lt;= +0.3 LogMAR) in visual acuity after BCL intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Epithelial Adverse Event (CEAE) Grade</measure>
    <time_frame>Up to approximately 3 years after initial dose of depatuxizumab mafodotin</time_frame>
    <description>The corneal epithelial adverse event (CEAE) rating scale is designed to record symptoms associated with corneal epitheliopathy caused by antibody-drug conjugates and to grade the severity of findings. The overall CEAE grade is measured on a scale of 0 to 5, with higher values being more severe, reflecting the impact of corneal abnormalities on visual activities of daily living (ADLs). Additional detailed information is collected for specific domains that are commonly affected, with the following ranges (each in order of increasing severity): ocular discomfort (0 - 4), photophobia (0 - 3), and reading (1 - 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Re-initiation of Depatuxizumab Mafodotin after Dose Interruption</measure>
    <time_frame>Up to approximately 3 years after initial dose of depatuxizumab mafodotin</time_frame>
    <description>Time from dose interruption until re-initiation or permanent discontinuation of depatuxizumab mafodotin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with Depatuxizumab Mafodotin Dose Interruptions due to OSEs</measure>
    <time_frame>Up to approximately 18 weeks after initial dose of depatuxizumab mafodotin</time_frame>
    <description>Participants with dose interruptions of depatuxizumab mafodotin due to ocular side effects (OSEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with Depatuxizumab Mafodotin Dose Reductions due to OSEs</measure>
    <time_frame>Up to approximately 18 weeks after initial dose of depatuxizumab mafodotin</time_frame>
    <description>Dose reductions of depatuxizumab mafodotin initiated due to OSEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Change from Baseline on LogMAR Scale</measure>
    <time_frame>Up to approximately 18 weeks after initial dose of depatuxizumab mafodotin</time_frame>
    <description>The Logarithm of the Minimum Angle of Resolution (LogMAR) scale measures visual acuity on a continuous scale, with a LogMAR value of 0 equivalent to 20/20 visual acuity. Normal vision is considered to be from -0.2 - 0.1; higher values indicate visual impairment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Arm B: Standard Steroids + Vasoconstrictor + Cold Compress</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B: Steroid eye drop plus vasoconstrictor eye drop and cold compress plus depatuxizumab mafodotin during both the chemoradiation therapy (RT and TMZ) and the adjuvant therapy [TMZ] periods of this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A: Standard Steroid (SS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: Steroid Eye Drops plus depatuxizumab mafodotin during both the chemoradiation therapy (radiation [RT] and temozolomide [TMZ]) and the adjuvant therapy [TMZ] periods of this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Enhanced Steroids+Vasoconstrictor+Cold Compress (ES/VC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm C: Steroid Eye Drop plus ophthalmic steroid ointment plus vasoconstrictor eye drop and cold compresses plus depatuxizumab mafodotin during both the chemoradiation therapy (RT and TMZ) and the adjuvant therapy [TMZ] periods of this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroid eye drop</intervention_name>
    <description>solution, eye drop</description>
    <arm_group_label>Arm A: Standard Steroid (SS)</arm_group_label>
    <arm_group_label>Arm B: Standard Steroids + Vasoconstrictor + Cold Compress</arm_group_label>
    <arm_group_label>Arm C: Enhanced Steroids+Vasoconstrictor+Cold Compress (ES/VC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ophthalmic steroid ointment</intervention_name>
    <description>ointment</description>
    <arm_group_label>Arm C: Enhanced Steroids+Vasoconstrictor+Cold Compress (ES/VC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>radiation</description>
    <arm_group_label>Arm A: Standard Steroid (SS)</arm_group_label>
    <arm_group_label>Arm B: Standard Steroids + Vasoconstrictor + Cold Compress</arm_group_label>
    <arm_group_label>Arm C: Enhanced Steroids+Vasoconstrictor+Cold Compress (ES/VC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>oral</description>
    <arm_group_label>Arm A: Standard Steroid (SS)</arm_group_label>
    <arm_group_label>Arm B: Standard Steroids + Vasoconstrictor + Cold Compress</arm_group_label>
    <arm_group_label>Arm C: Enhanced Steroids+Vasoconstrictor+Cold Compress (ES/VC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>depatuxizumab mafodotin</intervention_name>
    <description>infusion</description>
    <arm_group_label>Arm A: Standard Steroid (SS)</arm_group_label>
    <arm_group_label>Arm B: Standard Steroids + Vasoconstrictor + Cold Compress</arm_group_label>
    <arm_group_label>Arm C: Enhanced Steroids+Vasoconstrictor+Cold Compress (ES/VC)</arm_group_label>
    <other_name>ABT-414</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cold compress</intervention_name>
    <description>cold compress</description>
    <arm_group_label>Arm B: Standard Steroids + Vasoconstrictor + Cold Compress</arm_group_label>
    <arm_group_label>Arm C: Enhanced Steroids+Vasoconstrictor+Cold Compress (ES/VC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasoconstrictor eye drop</intervention_name>
    <description>solution, eye drop</description>
    <arm_group_label>Arm B: Standard Steroids + Vasoconstrictor + Cold Compress</arm_group_label>
    <arm_group_label>Arm C: Enhanced Steroids+Vasoconstrictor+Cold Compress (ES/VC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed glioblastoma (GBM) histologically proven, World Health Organization
             (WHO) grade IV GBM or WHO grade IV gliosarcoma.

          -  Tumors must demonstrate epidermal growth factor receptor (EGFR) amplification.

          -  Tumors must be supratentorial in location.

          -  Participant must have recovered from the effects of surgery, postoperative infection,
             and other complications; has no significant post-operative hemorrhage.

          -  Participant has a Karnofsky performance status (KPS) of 70 or higher.

          -  Participant has adequate bone marrow, renal, and hepatic function.

          -  Electrocardiogram without evidence of acute cardiac ischemia &lt;= 21 days prior to
             randomization.

          -  Participant has a life expectancy of &gt;= 3 months.

        Exclusion Criteria:

          -  Participants with newly diagnosed GBM: has received prior chemotherapy or radiotherapy
             for cancer of the head and neck region; has received prior treatment with Gliadel
             wafers or any other intratumoral or intracavitary treatment.

          -  Participant has hypersensitivity to any component of TMZ or dacarbazine.

          -  Participant has received anti-cancer therapy (including chemotherapy, immunotherapy,
             radiotherapy, hormonal, biologic, or any investigational therapy) within 5 years of
             Study Day 1.

          -  Participant has clinically significant uncontrolled condition(s) as described in the
             protocol.

          -  Participant has any medical condition which in the opinion of the investigator places
             the participant at an unacceptably high risk for toxicities.

          -  Participant has had another active malignancy within the past 3 years except for any
             cancer considered cured or non-melanoma carcinoma of the skin.

          -  Participant has a history of herpetic keratitis.

          -  Participant is not suitable for receiving ocular steroids with conditions as described
             in the protocol.

          -  Participant has had laser-assisted in situ keratomileusis (LASIK) procedure within the
             last 1 year or cataract surgery within the last 3 months.

          -  Participant has a visual condition that compromises the ability to accurately measure
             visual acuity or assess visual activities of daily living (vADLs).

          -  Participant has hepatitis B virus or hepatitis C virus infection.

          -  Participant not receiving treatment with highly active antiretroviral therapy (HAART)
             when positive for human immunodeficiency virus (HIV).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Usc /Id# 164235</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center /ID# 164234</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center /ID# 171003</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northshore University Health System-Evanston /ID# 164221</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CDH-Delnor Health System /ID# 169909</name>
      <address>
        <city>Warrenville</city>
        <state>Illinois</state>
        <zip>60555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center /ID# 164220</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3729</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Ins, Carolina Me /ID# 171271</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Health Science Ctr-Houston /ID# 164223</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Medical Center- Temple /ID# 170792</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital /ID# 169673</name>
      <address>
        <city>Saint Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle /ID# 169672</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital /ID# 169674</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital /ID# 169671</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Heidelberg /ID# 169970</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig /ID# 169969</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Univ. Regensburg /ID# 169963</name>
      <address>
        <city>Regensburg</city>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Tubingen /ID# 169965</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum /ID# 170152</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht /ID# 170149</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Found /ID# 207752</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital - BIRMINGHAM /ID# 200657</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital /ID# 200662</name>
      <address>
        <city>Cottingham</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital /ID# 203040</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
    <country>France</country>
  </removed_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 26, 2018</study_first_submitted>
  <study_first_submitted_qc>January 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma Multiforme (GBM)</keyword>
  <keyword>cancer</keyword>
  <keyword>chemoradiation therapy</keyword>
  <keyword>epidermal growth factor receptor-amplified glioblastoma</keyword>
  <keyword>radiation</keyword>
  <keyword>temozolomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Vasoconstrictor Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

